Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Serve H, et al. Among authors: kramer a. J Clin Oncol. 2013 Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897964 Clinical Trial.
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
Schaich M, Röllig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H, Schäfer-Eckart K, Aulitzky W, Kaufmann M, Bodenstein H, Tischler J, Ho A, Krämer A, Bornhäuser M, Schetelig J, Ehninger G. Schaich M, et al. Among authors: kramer m, kramer a. J Clin Oncol. 2011 Jul 1;29(19):2696-702. doi: 10.1200/JCO.2010.33.7303. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606413 Clinical Trial.
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
Röllig C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer E, Müller-Tidow C, Berdel WE, Ritter B, Pflüger KH, Kramer M, Haibach M, Ehninger G, Serve H, Krause SW. Röllig C, et al. Among authors: kramer m, kramer a. Leuk Lymphoma. 2012 Jun;53(6):1062-7. doi: 10.3109/10428194.2011.637210. Epub 2011 Dec 7. Leuk Lymphoma. 2012. PMID: 22054287
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Balss J, Pusch S, Beck AC, Herold-Mende C, Krämer A, Thiede C, Buckel W, Langhans CD, Okun JG, von Deimling A. Balss J, et al. Among authors: kramer a. Acta Neuropathol. 2012 Dec;124(6):883-91. doi: 10.1007/s00401-012-1060-y. Epub 2012 Nov 2. Acta Neuropathol. 2012. PMID: 23117877
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H. Müller-Tidow C, et al. Among authors: kramer a. Br J Haematol. 2013 Oct;163(2):214-22. doi: 10.1111/bjh.12518. Epub 2013 Aug 16. Br J Haematol. 2013. PMID: 24033250 Free article. Clinical Trial.
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Döhner H, et al. Among authors: kramer a. Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8. Blood. 2014. PMID: 25006120 Free PMC article. Clinical Trial.
2,985 results